McKesson

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade McKesson 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About MCK

McKesson Corp. engages in providing healthcare services. It operates through the following segments: U.S. 

CEO
Brian Scott Tyler
CEOBrian Scott Tyler
Employees
45,000
Employees45,000
Headquarters
Irving, Texas
HeadquartersIrving, Texas
Founded
1833
Founded1833
Employees
45,000
Employees45,000

MCK Key Statistics

Market cap
109.08B
Market cap109.08B
Price-Earnings ratio
27.51
Price-Earnings ratio27.51
Dividend yield
0.33%
Dividend yield0.33%
Average volume
774.18K
Average volume774.18K
High today
$895.58
High today$895.58
Low today
$883.69
Low today$883.69
Open price
$892.50
Open price$892.50
Volume
617.07K
Volume617.07K
52 Week high
$895.58
52 Week high$895.58
52 Week low
$558.13
52 Week low$558.13

Stock Snapshot

The current McKesson(MCK) stock price is $883.69, with a market capitalization of 109.08B. The stock trades at a price-to-earnings (P/E) ratio of 27.51 and offers a dividend yield of 33.4%.

As of 2025-11-28, McKesson(MCK) stock has fluctuated between $883.69 and $895.58. The current price stands at $883.69, placing the stock 0.0% above today's low and -1.3% off the high.

The McKesson(MCK)'s current trading volume is 617.07K, compared to an average daily volume of 774.18K.

During the past year, McKesson(MCK) stock moved between $558.13 at its lowest and $895.58 at its peak.

During the past year, McKesson(MCK) stock moved between $558.13 at its lowest and $895.58 at its peak.

MCK News

Simply Wall St 17h
Is McKesson’s 41.7% Price Surge Backed by Its Specialty Drug Expansion?

Ever wondered if McKesson’s rapid ascent means it is still a good buy, or if the best opportunities are already in the rearview mirror? In just the past year,...

Is McKesson’s 41.7% Price Surge Backed by Its Specialty Drug Expansion?
Simply Wall St 2d
McKesson: Valuation Spotlight as Analyst Upgrades and Specialty Expansion Drive Fresh Investor Interest

McKesson (MCK) just expanded its specialty product lineup as Iterum Therapeutics announced that ORLYNVAH is now available for physicians through McKesson’s dist...

McKesson: Valuation Spotlight as Analyst Upgrades and Specialty Expansion Drive Fresh Investor Interest

Analyst ratings

83%

of 18 ratings
Buy
83.3%
Hold
11.1%
Sell
5.6%

People also own

Based on the portfolios of people who own MCK. This list is generated using Robinhood data, and it’s not a recommendation.
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer.